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Abstract
Purpose We evaluated the effect of renal impairment (RI) on
the pharmacokinetics of telavancin and hydroxypropylbetadex
(excipient in the telavancin drug product).
Methods Adults with normal, mild, moderate or severe RI or
end-stage renal disease (ESRD) receiving haemodialysis were
included in two open-label, phase I studies of single-dose
telavancin at 7.5 mg/kg (study A, n=29) or 10 mg/kg (study
B, n=43). Pharmacokinetic analysis of telavancin and
hydroxypropylbetadex plasma concentration versus time was
performed in these subjects.
Results The results in studies A and B were similar:
telavancin systemic exposure (area under the concentration–
time curve from 0 to infinity [AUC0–∞]) increased with RI.
Telavancin half-life (h, mean±SD) increased in subjects with
severe RI compared with subjects with normal renal function
from 6.9±0.6 in study A and 6.5±0.9 in study B to 14.5±1.3
and 11.8±6.7, respectively. Conversely, clearance (ml/h/kg,
mean±SD) decreased in subjects with severe RI compared
with subjects with normal renal function from 13.7±2.1 in
study A and 17.0±3.2 in study B to 6.18±0.63 and 6.5±1.5,
respectively. Systemic exposures for hydroxypropylbetadex
also increased with severity of RI.
Conclusions Results from two independent phase 1 studies
suggest that dose adjustment of telavancin is required in sub-
jects with varying degrees of RI.
Keywords Telavancin . Lipoglycopeptide . Renal
impairment . Pharmacokinetics . Hydroxypropylbetadex
Introduction
Antibiotic resistance amongGram-positive bacteria, including
staphylococci, has necessitated the development of new anti-
biotics. Vancomycin, a glycopeptide antibiotic, has been the
drug of choice to treat methicillin-resistant Staphylococcus
aureus infections. The increasing prevalence of multidrug-
resistant strains, including those that are resistant to vancomy-
cin, has resulted in the development of the lipoglycopeptide
class of antibiotics, which have a lipophilic side chain linked
to a glycopeptide backbone. Members of this class of antibi-
otics include oritavancin, dalbavancin and telavancin.
Telavancin is a bactericidal lipoglycopeptide antibiotic
with activity against clinically relevant Gram-positive bacteria
[1]. The antimicrobial activity of telavancin results from a dual
mode of action, including inhibition of peptidoglycan synthe-
sis and disruption of the functional integrity of the bacterial
membrane [2, 3]. In the USA and Canada, intravenous (i.v.)
telavancin is approved for the treatment of adult patients with
complicated skin and skin structure infections caused by sus-
ceptible Gram-positive bacteria [4, 5]. In Europe, telavancin is
approved for the treatment of nosocomial pneumonia, includ-
ing ventilator-associated pneumonia, known or suspected to
be caused by methicillin-resistant S. aureus when other alter-
natives are unsuitable [6], and for the treatment of hospital-
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acquired bacterial pneumonia and ventilator-associated bacte-
rial pneumonia due to S. aureus when other alternatives are
not suitable in the USA [5]. In healthy adult volunteers,
telavancin at 7.5–15 mg/kg/day administered as an i.v. infu-
sion displayed linear pharmacokinetics, with an elimination
half-life (t½) averaging 7 h and trough plasma concentrations
exceeding the minimum concentration required to inhibit the
growth of 90 % of organisms for key Gram-positive patho-
gens [7, 8]. Following i.v. administration, telavancin is largely
excreted intact in urine (82 % after a single administration of
10 mg/kg) [9], and no significant gender- or age-related dif-
ferences in telavancin pharmacokinetics have been observed
in healthy volunteers [8, 10]. Co-administration of telavancin
with the renally excreted antibiotics aztreonam or piperacillin/
tazobactam had no significant effect on the pharmacokinetics
of any of the drugs [11]. The pharmacokinetic profile supports
a once-daily dosage strategy for telavancin in patients with
normal renal function.
It was expected that systemic exposure to telavancin would be
greater in patientswith reduced creatinine clearance (CLcr) than in
those with normal CLcr. In order to develop dosage recommen-
dations, we examined the pharmacokinetic profile of telavancin
and the drug product excipient hydroxypropylbetadex, used in
telavancin’s formulation to aid solubilisation, in subjects with
various degrees of renal impairment in two phase 1 trials, Studies
103a (Theravance, Inc.) and 2403 (Astellas PharmaEuropeB.V.),
herein referred to as study A and study B, respectively.
Materials and methods
Study designs
Study A was a phase 1, open-label, single-arm, single-dose,
two-centre study (Quintiles Limited, Guy’s Drug Research
Centre, London, UK and MDS Pharma Services, New
Orleans, LA, USA) that examined the effects of renal impair-
ment on telavancin pharmacokinetics in subjects with varying
degrees of renal impairment. Study B was a phase 1, open-
label, single-dose, three-centre study in Poland (SP ZOZ
Szpital Praski, Warsaw; SP Specjalistyczny Szpital, Zachodni,
Grodzisk Mazowiecki; and SZP ZOZ, Wołominie, Wołomin)
that investigated the effect of mild, moderate and severe renal
impairment on the pharmacokinetics of telavancin compared
with subjects with normal renal function.
Ethics
The study protocols were approved by the institutional review
board at each participating site, and both studies were con-
ducted in full compliance with the principles of the Interna-
tional Conference on Harmonization of Technical Require-
ments for Registration of Pharmaceuticals for Human Use,
Good Clinical Practice and the Declaration of Helsinki. Writ-
ten informed consent was obtained from all subjects.
Subjects
Subjects includedmen and non-pregnant women and, in study
A or B, respectively, were ≥18 years or 20–79 years of age
with a body mass index of 18–36 or 18.5–34 kg/m2. Subjects
were either healthy or had mild, moderate or severe renal
impairment. Subjects were excluded if they had a history of
any relevant pulmonary, haematologic, hepatic, immunologic,
endocrine, metabolic, rheumatic, neurologic or psychiatric
disorder. Subjects with stable, adequately treated medical con-
ditions could be enrolled provided that their medical regimen
was unchanged in the 3 months before study participation and
that participation did not place them at increased risk of ad-
verse events.
Subjects were assigned to the renal impairment strata based
on assessment during pre-study screening. For study A, strata
assignment was based on CLcr calculated using the Cockcroft-
Gault (C–G) equation [12] (Table 1). For study B, assignment
was based on the estimated glomerular filtration rate (eGFR)
using the Modification of Diet in Renal Disease formula [13]
(Table 1). Summary statistics for Study B were also prepared
using the C–G equation [12] with and without normalization
to body surface area. Creatinine assays were performed at
each clinical site using UV absorbance assays at 512 nm to
detect the yellow–red complex formed from the reaction of
creatinine and picric acid under alkaline conditions.
In subjects with end-stage renal disease (ESRD),
haemodialysis was initiated 2–4 h after study drug adminis-
tration (study A only). Haemodialysis sessions were 4 h in
duration, and when possible, a similar type of dialyzer at a
similar blood flow rate was used across haemodialysis
subjects.
Table 1 Determination of renal function by estimated pre-dose creati-









Mild 51–80 60 to 89
Moderate 30–50 30 to 59




ESRD end-stage renal disease,CLcr creatinine clearance, eGFR estimated
glomerular filtration rate, NA not applicable
a Cockcroft-Gault equation
bModification of Diet in Renal Disease formula
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Treatments
Telavancin for injection was supplied as a sterile, lyophilized
powder for i.v. injection. Eachmillilitre of formulated solution
contained approximately 10 mg of telavancin, 100 mg of
hydroxypropylbetadex (to improve solubility) and 12.5 mg
mannitol as excipients. In study A, subjects with renal impair-
ment received a single, 1-h infusion of telavancin 7.5 mg/kg
on day 1. In study B, subjects received a single, 1-h infusion of
telavancin 10 mg/kg on day 1. In study B, the actual dose of
telavancin administered was approximately 10 % less than
planned due to a residual amount of solution remaining within
the infusion system.
Pharmacokinetic assessments—sample collection
Plasma Blood samples (5–6 ml) were collected in sodium
heparin glass tubes and stored chilled until the plasma was
harvested by centrifugation and stored at approximately
–70 °C or below until transferred frozen to a central laboratory
for analysis. For subjects with varying degrees of renal im-
pairment, samples were collected in study A pre-infusion, at 1,
2, 4, 6, 8, 12, 24, 36 and 48 h after the start of infusion for all
groups and also at 72 and 96 h post-infusion for subjects with
severe renal impairment or ESRD. In study B, samples were
collected pre-infusion and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12,
16, 24, 36, 48, 60, 72, 84 and 96 h post-dose.
Urine Because the urine assay for telavancin was not opti-
mized at the time of study A, no results were reported; the
assays were subsequently conducted in study B, where sam-
ples were collected pre-infusion and at 0–6, 6–12, 12–24, 24–
36, 36–48, 48–60, 60–72, 72–84 and 84–96 h after the start of
infusion. Aliquots were collected and stored at −70 °C or
lower.
ESRD For subjects with ESRD (study A), a sample from the
inflow to the dialyzer on the arterial side was collected before
dialysis and at 1, 2, 3 and 4 h after the start of dialysis; dial-
ysate fluid samples (10 ml) were collected before and at 30-
min intervals during dialysis. Plasma samples were also col-
lected at 0, 60, 120, 180 and 240 min following the start of
dialysis.
Analytical methods
In study A, plasma samples were analysed at a central labora-
tory (Covance Central Laboratory Services, Indianapolis, IN,
USA) using a validated liquid chromatography–mass spec-
trometry (LC–MS) method for telavancin, which has been
previously described [6]. The method was linear over the
range 0.25–100 μg/ml and the lower limit of quantification
(LLQ) was 0.25 μg/ml. Dialysate samples from study Awere
analysed at a separate central laboratory (Covance Laborato-
ries, Madison, WI, USA) using a similar validated LC–MS
method. The method was linear over the range of 0.1–
25.0 μg/ml, and the LLQ in human dialysate for telavancin
was 0.1 μg/ml. Study samples outside the calibration range
were diluted and re-assayed. Dilution QC samples were in-
cluded in batches where samples were diluted prior to analy-
sis. The inter-day precision and accuracy of quality controls
and standards during the validation was better than 13 % for
all concentrations evaluated. Plasma concentrations of
hydroxypropylbetadex were determined at Theravance, Inc.
(South San Francisco, CA, USA) using high-performance
LC (HPLC) with fluorescence analysis. Solid-phase extrac-
tion was used for sample preparation, after which
hydroxypropylbetadex was complexed with a mobile phase
additive (1-napthol). The resulting hydroxypropylbetadex
sample peaks were then quantified against external standards.
The standard curve range for hydroxypropylbetadex was 10–
800 μg/ml, with an LLQ of 10 μg/ml.
In study B, plasma and urine concentrations of telavancin
were analysed at Pharmaceutical Product Development (Rich-
mond, VA, USA) after receipt of all samples using a validated
LC–MS/MS method. The method was linear over the range
0.1–25 μg/ml for telavancin in plasma (LLQ 0.1 μg/ml) and
0.25–80 μg/ml (LLQ 0.25 μg/ml) for telavancin in urine. The
inter- and intra-assay precision and accuracy of quality con-
trols and standards during the validation was within 7.6 % in
plasma and 10.2 % in urine. Plasma concentrations of
hydroxypropylbetadex were determined at Pharmaceutical
Research Associates (Assen, The Netherlands) by a validated
HPLC fluorescence method.
Pharmacokinetic analyses
Pharmacokinetic parameters of telavancin were determined by
non-compartmental analysis using WinNonlin version 4.0.1
(study A) and version 5.3 (study B) (Pharsight, Mountain
View, CA, USA); SAS version 9.1.3 (SAS Institute, Cary,
NC, USA) was used to analyse the urine pharmacokinetic
parameters in study B. Only samples with measureable con-
centrations were used for the purpose of calculating the phar-
macokinetic parameters in both studies. Plasma pharmacoki-
netic parameters were calculated as previously described [7].
The CL reported for ESRD is the CL for the subjects (i.e.,
includes residual clearance and any dialysis clearance).
Clearance of telavancin by haemodialysis (CLHD) was cal-
culated as CLHD = QD × (CTLV – DTLV) ÷ (CTLV), where QD
was the dialysate flow rate, DTLV was the telavancin concen-
tration in the dialysate effluent and CTLV was the telavancin
concentration in the arterial blood entering the dialyzer. Dia-
lyzers used included the PSN 210 and the 2K 2.5 Dialysate
(both Gambro). The dialysate flow rate was 800 mL/min, and
blood flow rates in patients ranged from 300 to 500 mL/min.
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Also, in study A, the cumulative amount of telavancin esti-
mated in dialysis fluid was determined by multiplying the
telavancin concentration in aliquots collected at 30-min inter-
vals by the dialysate volume per collection period and then
summing the individual hourly excretion amounts. In study B,
the percentage of the dose excreted in urine was calculated as
Ae0–t% = Ae0–t/dose×100 % and Ae0–∞% = Ae0–∞/dose×
100 %. Renal CL (CLR) was calculated as CLR = Ae ÷
AUC, with Ae and AUC both taken over the same interval
and where Ae is amount of telavancin excreted over time, and
AUC is area under the concentration–time curve.
Protein binding assay
Protein binding was assayed in study A. The plasma protein
binding of telavancin 50 μg/ml (spiked with 1 μg/ml of [14C]
telavancin [Vitrax, Placentia, CA, USA]) was determined
in vitro by analysing pre-infusion plasma samples under equi-
librium dialysis. The percent of protein binding was calculated
as follows:
%bound ¼ donor−receptorð Þ  donorð Þ  100%; and
% unbound ¼ receptor  donorð Þ  100 % ;
where donor = plasma side concentration and receptor = buff-
er side concentration.
Statistical analyses
Summary statistics were calculated for pharmacokinetic pa-
rameters by renal impairment group in both studies.
Concentration values within treatment and time point were
evaluated for outliers using Tukey’s inter-quartile range meth-
od [14]. Source documentation was reviewed for all identified
outliers for supportive evidence that would deem the values
unreliable.
All outliers were included in the analyses. For all summa-
ries and analyses, the baseline value was the last assessment
taken prior to the administration of the dose of study drug.
Results
Subjects
In all, 29 (study A) and 43 (study B) subjects with varying
degrees of renal impairment were enrolled. The mean CLcr in
each group of subjects with renal impairment was within the
pre-defined range (Table 1), enabling comparative assessment
of telavancin pharmacokinetics with respect to level of renal
function. Demographic parameters for each group are present-
ed in Table 2. One subject with mild renal impairment from
study A received only a partial dose (approximately two
thirds) of telavancin due to a flushing reaction on the upper
body. This subject was excluded from pharmacokinetic eval-
uation but was included in the safety analysis.
Pharmacokinetics
Telavancin
For both studies, following a single, 1-hour i.v. infusion of
telavancin 7.5 mg/kg (study A) or 10 mg/kg (study B), plasma
telavancin concentrations declined in an apparent bi-
exponential manner, with a slower decline in subjects with
greater degrees of renal impairment (Fig. 1a, b; study A and
B, respectively). The distribution of telavancin, as measured
by mean maximum concentration and volume at steady state
(Vss), was similar in healthy subjects and those with varying
degrees of renal impairment (Table 3). In subjects with severe
renal impairment or ESRD, mean plasma telavancin CL was
reduced by more than 50 %, and t1/2 almost doubled in both
studies. A strong relationship was found between plasma CL
of telavancin and CLcr over the entire range of renal function
(Fig. 2a): r2=0.76 in study A and r2=0.62 in study B. Based
on comparison of AUC from time zero to infinity (AUC0–∞)
estimates in healthy subjects, systemic exposure to telavancin
in study A/study B was increased by 13/12, 29/74 and 118/
160 % in subjects with mild, moderate and severe renal
impairment, respectively. The corresponding increase in
AUC0–∞ in the ESRD group in study A was 79 %. In
subjects who underwent haemodialysis on the same day
as administration of 7.5 mg/kg of telavancin, approximately
6 % of the total administered dose was removed by dialysis
session. The dialysis clearance was estimated to be 4.5 ml/min
(271 ml/h; approximately 25 % of clearance in normal
subjects).
Plasma protein binding of telavancin in vitro was deter-
mined for all subjects who provided a pre-dose plasma
sample in study A only. There were no appreciable dif-
ferences among renal impairment groups in the degree
of telavancin protein binding: the average binding of
telavancin to plasma proteins was approximately 87 % in all
groups (Table 3).
Urinalysis results from study B (Table 4) show that the
excretion of telavancin (Ae0–t, normalized to a telavancin
10 mg/kg dose) decreased with declining renal function from
a mean (± standard deviation) of 436±91 mg in subjects with
normal renal function to 207±62 mg in subjects with severe
renal impairment, corresponding to 62.8 and 28.1 % of the
dose, respectively. All other values (Ae0–∞, Ae0–∞%) reflected
the same trend. CLR decreased with renal function from 10.2±
1.8 to 1.8±0.6 ml/h/kg, becoming significant in subjects with
moderate or severe renal impairment (P<0.0001).
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Hydroxypropylbetadex
In each renal impairment group, the concentration of
hydroxypropylbetadex decreased over time in a log-linear man-
ner, indicating first-order disposition processes (Fig. 1c, d; study
A and B, respectively). The CL decreased with declining renal
function (Table 3), and a linear relationship was found between
plasma clearance of hydroxypropylbetadex and CLcr (Fig. 2b).
Plasma clearance of hydroxypropylbetadex was progressively
lower in the groups of subjects with increasing degrees of renal
impairment and decreased by up to 88 % in study A subjects
with ESRD (84 % in study B). Thus, after a single, 1-hour i.v.
infusion, plasma levels of hydroxypropylbetadex remained
measurable for the longest period in the groups with the poorest
kidney function: hydroxypropylbetadex t1/2 was about three
(study A) to six (study B) times as high in subjects with severe
renal impairment and 12-fold higher in those with ESRD (study
A only) relative to those with normal renal function (Table 3).
A plot of total body CL versus CLcr shows an excellent
correlation between the two parameters, with complete over-
lap of the results of the two studies: telavancin (Fig. 2a) and
hydroxypropylbetadex (Fig. 2b).
Table 2 Demographics and baseline characteristics of phase I study volunteers by degree of renal impairment











Age (years) 51±9/53±6 59±15/57±5 70±9/65±6 58±12/67±9 47±6/NA
Weight (kg) 79±10/70±12 76±15/70±14 69±11/77±13 80±17/73±15 81±23//NA
Height (cm) 175±6/164±7 169±7/165±13 168±11/162±8 173±15/163±6 172±7/NA
BMI (kg/m2) 26±2/26±3 26±4/25±3 25±4/29±4 27±2/28±5 27±7/NA
CLcr (mL/min)/
eGFR (mL/min/1.73 m2)b
94±11/110±20 67±9/ 81±6 40±7/48±7.5 22±7/ 21±5 10±4/NA
BMI body mass index, CLcr creatinine clearance, ESRD end-stage renal disease, NA not applicable, SD standard deviation
a One subject was excluded from pharmacokinetic evaluation due to receipt of an incomplete dose of telavancin but was included in the safety/
demographic population
b See Table 1 for definitions of CLcr (mL/min) from study A and eGFR (mL/min/1.73 m
2 ) from study B
Table 3 Mean (±standard deviation) non-compartmental pharmacokinetic parameters of telavancin and the excipient hydroxypropylbetadex in
subjects with varying degrees of renal function (see Table 1 for definitions CLcr (ml/min) from study A and eGFR (ml/min/1.73 m
2) from study B)
Parameter Study A/study B, mean±standard deviation
Normal (n=6/14) Mild (n=6/13) Moderate (n=6/8) Severe (n=4/8) ESRDa (n=6/0)
Telavancin
Protein binding (%)a 86.5±1.3 87.5±1.0 87.8±1.1 86.7±1.2 87.6±1.0/0
t½ (h) 6.9±0.6/6.5±0.9 9.6±2.9/7.8±2.0 10.6±2.4/8.1±1.5 14.5±1.3/11.8±6.7 11.8±2.8/0
Cmax (μg/mL) 70.6±11.2/76.7±8.6 65.9±2.7/74.2±7.3 65.8±12.1/78.0±4.5 71.8±7.1/83.2±13.1 52.1±10.1/0
AUC0–∞ (μg h/mL) 560±93/539±99 633±101/606±139 721±200/936±182 1220±120/1397±297 1010±341/0
CL (mL/h/kg) 13.7±2.1/17.0±3.2 12.1±1.9/15.2±4.6 11.1±3.3/9.5±2.0 6.18±0.63/6.5±1.5 8.18±2.65/0
Vss (mL/kg) 131±16/155.4±30.2 157±19/159.5±34.5 156±24/157.8±41.7 136±10/ 141.9±17.7 157±27/0
Hydroxypropylbetadex
t½ (h) 3.02±1.56/2.15±0.35 4.96±6.22/2.47±0.55 4.18±1.27/5.09±2.07 9.84±3.62/12.2±2.8 37.2±8.72/0
Cmax (μg/mL) 344±61/386±51 476±83/367±37 565±172/453±58 517±36/479±57 290±59/0
AUC0–∞ (μg h/mL) 946±45/971±199 1880±1050/1083±275 2720±1190/2512±921 5440±1460/6385±1713 8510±2470/0
CL (mL/h/kg) 79.5±3.8/94.5±19.0 49.2±22.7/85.1±25.3 32.5±14.2/37.2±11.0 14.5±3.3/14.6±4.5 9.8±4.3/0
Vss (mL/kg) 263±101/277.7±148.2 182±51/248.6±61.8 160±71/228.2±56.1 183±23/227.8±32.7 473±70/0
The CL reported for ESRD is the CL for the subjects (i.e., includes residual clearance and any dialysis clearance)
AUC area under concentration-time curve, ESRD end-stage renal disease,Cmaxmaximum plasma concentration,CL clearance,CLcr creatinine clearance,
t½ terminal elimination half-life, Vss apparent volume of distribution at steady state
a Study A only
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Fig. 1 Mean plasma telavancin (TLV; a, b) and hydroxypropylbetadex (HPB; c, d) concentration–time profiles in subjects from studies A and B,
respectively, with normal renal function and those with mild impairment, moderate impairment, severe impairment, or end-stage renal disease (ESRD)
Table 4 Summary statistics of renal-related urinary pharmacokinetic parameters by renal function category (study B)
Parameter Mean±standard deviation
Normal renal function Mild renal impairment Moderate renal impairment Severe renal impairment
Telavancin
Ae0-t (mg)
a 436±91 397±100 368±91 207±62
Ae0-t% (%) 62.8±9.0 58.2±11.5 48.4±8.7 28.0±4.3
Ae0–∞ (mg)
a 435±91 396±100 375±96 208±60
Ae0–∞% (%) 62.7±9.1 58.2±11.6 48.4±9.3 28.2±3.9
CLR (mL/h/kg) 10.5±1.9 8.8±3.3 4.7±1.6 1.9±0.7
Hydroxypropylbetadex
Ae0-t, 10 mg (mg)
a 4801±1390 4292±1449 5190±709 4879±1112
Ae0-t% (%) 68.8±15.9 63.6±20.5 69.0±8.6 65.7±11.4
Ae0–∞ (mg)
a 4786±1487 4274±1470 5257±773 4969±1070
Ae0–∞ (%) 68.5±17.5 63.4±21.1 68.7±9.3 67.1±12.0
CLR (mL/h/kg) 62.9±15.4 51.4±19.4 26.5±7.6 10.0±4.1
a Normalized to a telavancin dose of 10 mg/kg
Ae0–t amount of telavancin excreted in the urine up to the last quantifiable sample, Ae0–∞ amount of telavancin excreted in the urine extrapolated to
infinity, CLR renal clearance
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Safety and tolerability
A single i.v. infusion of telavancin 7.5 mg/kg (study A) or
10 mg/kg (study B) was well tolerated in subjects with normal
renal function as well as in those with varying degrees of renal
impairment. Treatment-emergent adverse events (TEAEs) in
study A and B, respectively, were reported by 17/29 (59 %)
and 7/43 (16.3 %) of the subjects, including 5/6 (83 %) and 0/
14 (0 %) with normal renal function, 4/7 (57 %) and 1/13
(7.7 %) with mild renal impairment, 3/6 (50 %) and 2/8
(25 %) with moderate renal impairment and 3/4 (75 %) and
4/8 (50 %) with severe impairment as well as 2/6 (33 %)
subjects with ESRD (study A only). The most common
TEAEs reported in study A were foamy urine (n=6),
dysgeusia (n=5), nausea (n=4), headache (n=3), dizziness
(n=2), abdominal distension (n=2) and somnolence (n=2).
One subject with mild renal impairment experienced flushing
of the upper body (consistent with ‘red man’ syndrome),
resulting in discontinuation of the infusion after two thirds
of the dose had been administered. This subject was treated
with i.v. chlorpheniramine and recovered fully.
No clinically significant changes in haematology, blood
chemistry, urinalysis, vital signs, physical signs or electrocar-
diogram (ECG) were detected following telavancin administra-
tion. Similarly, no clinically significant abnormalities were de-
tected in ten subjects with various degrees of renal impairment
who underwent audiology assessments. In study B, the most
frequently reported event was ECG QT prolongation as ob-
served in three subjects (7.0 %), followed by increased blood
lactate dehydrogenase in two subjects (4.7 %); these were mild
and transient. Prolongation in ECGQT interval was reported in
two subjects with severe renal impairment and one subject with
moderate renal impairment; all cases were transient and report-
ed as abnormal and clinically significant by the investigator. No
serious adverse events were reported.
Discussion
There is an increase in AUC and t1/2 for telavancin and a
decrease in CL with increasing renal impairment, but no sub-
stantive change in maximum concentration after a single-dose
administration. Additionally, the data suggest that, while the
renal route is clearly important, other routes of elimination
may also be involved.
In study B, urine was collected for 96 h, which is more than
sufficient for complete excretion, based on the estimates of t½,
even in severe renal impairment. Despite this, only 28 % of the
administered dose was recovered unchanged, suggesting that
renal elimination of unchanged telavancin may not be the pri-
mary route of elimination in patients with moderate to severe
renal impairment. Following i.v. administration, telavancin is
largely excreted intact in urine (82 % after a single administra-
tion of 10mg/kg) [9], with the remaining dose being eliminated
as several hydroxylatedmetabolites. In subjects with increasing
renal impairment, the renal contribution to CL will be reduced
in favour of the metabolic component, resulting in a reduced
percentage of telavancin being recovered unchanged.
Based on previous data from subjects with normal renal
function, the t½ of hydroxypropylbetadex was 2.5±0.84 h (data
on file) [15]. In previously studied patients with severe renal
impairment, the t½ of hydroxypropylbetadex was 15.6±6.0 h,
and total CL was 0.67±0.2 mL/h/kg (data on file, referenced in
[15]), values that are consistent with the results of our study.
There was no clear change in Vss of hydroxypropylbetadex
with worsening renal function, although total body CL in-
creased in proportion to decreases in eGFR, indicating that
renal impairment reduces hydroxypropylbetadex CL, resulting
in an increase in AUC. However, given the dosage adjustment
in patients with moderate (CLcr 30–50 mL/min) and severe
(10–<30 mL/min) renal impairment, hydroxypropylbetadex
exposure is expected to be reduced.
In study A, approximately 6 % of the telavancin dose was
eliminated during a 4-h haemodialysis session, but the
Fig. 2 Correlation plots of creatinine clearance versus a telavancin and b
hydroxypropylbetadex total body clearance. CLcr was calculated using the
Cockcroft–Gault equation without normalization for body surface area
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calculated haemodialysis clearance is approximately 25 % of
total body CL. This observation suggests that a longer dura-
tion of dialysis might clear a larger proportion of drug dose.
Plasma concentrations of hydroxypropylbetadex were also
higher in subjects with renal impairment in both studies as
well as in haemodialysis patients (study A only). However,
dialysis is known to remove hydroxypropylbetadex [15]. The
differential effect of renal impairment on telavancin exposure
versus hydroxypropylbetadex exposure may be due to a lack
of metabolic clearance.
To conclude, dose adjustment of telavancin in patients with
renal impairment is supported by the findings of two indepen-
dent phase 1 studies in subjects with varying degrees of renal
impairment. Telavancin 10 mg/kg every 24 h is recommended
for patients with CLcr >50 mL/min, 7.5 mg/kg every 24 h for
patients with CLcr 30–50mL/min and 10mg/kg every 48 h for
those with CLcr 10–30mL/min. Results from two independent
phase 1 studies suggest that dose adjustment of telavancin is
required in subjects with varying degrees of RI.
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